Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
24,446 total articles
Pliant Therapeutics announced a poster presentation at the 2026 ASCO Annual Meeting highlighting their Phase 1b FORTIFY trial, which is evaluating PLN-101095, a dual integrin inhibitor, in combination with pembrolizumab for patients with immune checkpoint inhibitor refractory solid tumors. The trial is actively enrolling multiple patient cohorts an…
VCI Global Limited disclosed that NASDAQ notified the company of a delayed filing of its 2025 Form 20-F report. The company had previously filed a Form 12b-25 advising the SEC of the delay due to additional time needed for financial review. VCI Global is submitting a compliance plan to NASDAQ and may receive an extension of up to 180 days to regain…
Aktis Oncology announced first-in-human imaging and dosimetry results for AKY-2519, a novel miniprotein radioconjugate targeting B7-H3 expressing tumors, including metastatic castration-resistant prostate cancer and other solid tumors. Data presented at ASCO 2026 demonstrate robust tumor uptake and limited normal tissue exposure, indicating a favor…
Jupiter Neurosciences announced the closing of a $2 million registered direct offering, issuing over 7 million shares to strengthen its cash position. The capital raise extends the company's cash runway to fund its Phase 2a clinical trial for Parkinson’s disease and supports debt reduction efforts to improve shareholder equity. Additionally, funds …
Black Diamond Therapeutics announced positive Phase 2 clinical trial results of silevertinib, an oral brain-penetrant EGFR inhibitor, in treatment-naïve patients with non-small cell lung cancer (NSCLC) harboring non-classical EGFR mutations. The study demonstrated a median progression-free survival of 15.2 months, a 60% objective response rate, and…
Autolus Therapeutics announced publication and upcoming presentation of clinical data from the FELIX Phase Ib/II trial on their T cell therapy candidate obe-cel at the ASCO 2026 meeting. The data shows a 59% overall response rate and median duration of response of 42.6 months in adult patients with relapsed/refractory B-cell acute lymphoblastic leu…
Equus Total Return, Inc. announced its net asset value (NAV) increased to $1.50 per share as of March 31, 2026, up from $1.19 at the end of 2025. The rise was largely due to a $5 million increase in the value of its holdings in Morgan E&P, Inc., benefiting from higher crude oil prices. Despite a slight decrease in the value of its holdings in Citro…
Eikon Therapeutics, Inc. (Nasdaq: EIKN), a late-stage clinical biopharmaceutical company focused on oncology, announced the availability of six abstracts for presentation at the 2026 American Society of Clinical Oncology Annual Meeting. The presentations will highlight updated clinical data and progress for Eikon's advanced drug candidates, includi…
North American Construction Group Ltd. reported the outcomes of its Annual and Special Meeting held on May 20, 2026. Shareholders elected seven directors, approved KPMG LLP as independent auditors, ratified an Advance Notice Bylaw, and passed a non-binding advisory vote on executive compensation. The company operates in heavy civil construction and…
Moleculin Biotech's pooled cardiac safety data for its lead drug candidate Annamycin has been accepted for poster presentation at the 2026 ASCO Annual Meeting. The data shows no significant cardiotoxicity even at high cumulative doses, supporting the differentiated safety profile of Annamycin in treating acute myeloid leukemia and soft tissue sarco…
Regeneron announced positive Phase 1/2 LINKER-AL2 trial results for Lynozyfic (linvoseltamab) monotherapy in patients with relapsed or refractory systemic amyloid light chain (AL) amyloidosis. Lynozyfic demonstrated deep and rapid hematologic complete responses in all treated patients at the highest dose, with notable improvements in organ function…
Syndax Pharmaceuticals announced that four abstracts involving its FDA-approved menin inhibitor Revuforj (revumenib) have been accepted for presentation at the ASCO 2026 Annual Meeting. Key highlights include an oral presentation showing favorable outcomes in acute leukemia patients receiving revumenib post-hematopoietic stem cell transplantation a…
Akari Therapeutics announced positive preclinical data demonstrating that their lead antibody drug conjugate (ADC), AKTX-101, synergizes with KRAS inhibitors (including adagrasib) to enhance cytotoxic activity against KRAS-mutated pancreatic cancer models. Unlike traditional ADCs, AKTX-101 uses a novel RNA spliceosome modulating payload (PH1) that …
AerSale Corporation announced that CFO Martin Garmendia will present at the upcoming 2026 Jefferies Aftermarket MRO Virtual Summit and hold investor meetings. The company provides aviation aftermarket services including aircraft and engine sales, leasing, and MRO services. The webcast presentation will be available live and replayed on the company’…
Navient Corporation declared a second quarter 2026 dividend of $0.16 per common share, payable on June 19, 2026, to shareholders of record as of June 5, 2026. The company continues to focus on responsible lending, refinancing options, and financial services through its Earnest business unit.
Cardiff Oncology announced a webcast on June 3, 2026, to discuss updated Phase 2 clinical trial data of Onvansertib, their PLK1 inhibitor drug candidate combined with standard-of-care treatments for first-line RAS-mutated metastatic colorectal cancer. Updated results show dose-dependent improvements in overall response rate and progression-free sur…
Legend Biotech announced multiple presentations at the ASCO 2026 meeting, including preliminary Phase 1 results for LB2102, a DLL3-targeted CAR-T therapy showing early activity in solid tumors like small cell lung cancer. Additional data on CARVYKTI (ciltacabtagene autoleucel) reinforces its efficacy in multiple myeloma, supporting ongoing studies …
Olema Oncology announced encouraging preliminary results from the Phase 1 clinical trial of OP-3136, a selective KAT6 inhibitor, showing tolerability and anti-tumor activity across multiple advanced solid tumors. The data support continued development of OP-3136 both as monotherapy and combined with current endocrine therapies in metastatic breast …
Compass Therapeutics announced encouraging Phase 1 trial results of CTX-8371, a novel bispecific antibody targeting PD-1 and PD-L1, demonstrating deep and durable responses in patients with advanced malignancies resistant to prior immune checkpoint inhibitors. The drug showed clinical activity in triple-negative breast cancer, Hodgkin lymphoma, and…
NVIDIA has announced its participation in two upcoming major financial community events: the TD Cowen 54th Annual Technology, Media, & Telecom Conference on May 28, 2026, and the BofA Global Technology Conference on June 4, 2026. The company will webcast these financial presentations live, providing investors and industry stakeholders with updates …
Immuneering Corporation announced a 17.3-month median overall survival in a Phase 2a trial of atebimetinib combined with chemotherapy in first-line metastatic pancreatic cancer patients. The treatment showed a tolerable safety profile with only chemotherapy-related Grade 3 or higher adverse events observed in 10% or more of patients. The company wi…
TruGolf Holdings reported a modest revenue decline to $5.0 million in Q1 2026 compared to $5.2 million in Q1 2025, with a slight drop in golf simulator sales offset by increased software contracts. The company reduced its net loss to $1.4 million from $2.7 million in the prior year quarter, driven by lower operating expenses and interest costs. Tru…
American Superconductor Corporation (AMSC) plans to release its fourth quarter and fiscal year 2025 financial results after market close on May 27, 2026, with a follow-up investor conference call on May 28, 2026. The company provides power control solutions targeting energy system optimization, grid reliability, naval fleet safety, and renewable en…
CVB Financial Corp., a top-performing California-based bank holding company with over $20 billion in assets, announced a leadership transition following its annual meeting. George A. Borba Jr., a long-serving director and Vice Chairman, has been appointed Chairman of the Board, succeeding Hal W. Oswalt who transitions to Vice Chairman. The company …
Seer, Inc.'s Board of Directors has unanimously rejected the revised unsolicited acquisition proposal from the Radoff-JEC Group, citing significant undervaluation and failure to reflect Seer's long-term growth prospects. The Board determined that the offer does not represent the best interests of shareholders. Seer continues to emphasize its positi…
